These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25846738)

  • 1. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
    Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
    Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
    Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
    Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer.
    Zhou Y; Wang M; Wu J; Jie Z; Chang S; Shuang T
    J Ovarian Res; 2015 Apr; 8():23. PubMed ID: 25887170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer.
    Liu L; Guo J; Yu L; Cai J; Gui T; Tang H; Song L; Wang J; Han F; Yang C; Chen C; Marks A; Wang Z
    Tumour Biol; 2014 Dec; 35(12):12619-26. PubMed ID: 25260883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma.
    Zou YT; Gao JY; Wang HL; Wang Y; Wang H; Li PL
    Genet Mol Res; 2015 Jul; 14(3):8766-77. PubMed ID: 26345808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Guo P; Xiong X; Zhang S; Peng D
    Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
    Ye G; Fu G; Cui S; Zhao S; Bernaudo S; Bai Y; Ding Y; Zhang Y; Yang BB; Peng C
    J Cell Sci; 2011 Feb; 124(Pt 3):359-68. PubMed ID: 21224400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
    Shuang T; Wang M; Shi C; Zhou Y; Wang D
    FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
    BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
    Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
    Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.